Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Neurometrix Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
NURO
Nasdaq
3841
https://www.neurometrix.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Neurometrix Inc
Q1 2023 NeuroMetrix Inc Earnings Call
- May 4th, 2023 1:17 am
NeuroMetrix Reports Q1 2023 Financial Results
- May 3rd, 2023 11:00 am
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
- Apr 28th, 2023 1:21 pm
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
- Mar 21st, 2023 1:00 pm
NeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021)
- Feb 25th, 2023 12:36 pm
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
- Feb 23rd, 2023 12:00 pm
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
- Feb 16th, 2023 7:58 pm
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
- Jan 23rd, 2023 2:00 pm
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
- Nov 8th, 2022 2:00 pm
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
- Nov 3rd, 2022 1:00 pm
NeuroMetrix Reports Q3 2022 Financial Results
- Oct 20th, 2022 11:00 am
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
- Oct 12th, 2022 7:47 pm
Companies Like NeuroMetrix (NASDAQ:NURO) Are In A Position To Invest In Growth
- Sep 25th, 2022 12:26 pm
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
- Sep 1st, 2022 1:00 pm
NeuroMetrix Reports Q2 2022 Financial Results
- Jul 21st, 2022 11:00 am
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
- Jul 14th, 2022 3:32 pm
NeuroMetrix Appoints Brad Fluegel to its Board of Directors
- Jun 28th, 2022 1:00 pm
Scroll